Abstract:Oral cancer is among the most prevalent cancers in the world. Moreover, it is one of the major health problems and causes of death in many regions of the world. The traditional treatment modalities include surgical removal, radiation therapy, systemic chemotherapy, or a combination of these methods. In recent decades, there has been significant interest in intraoral site-specific chemoprevention via local drug delivery using polymeric systems. Because of its easy accessibility and clear visibility, the oral mu… Show more
“…Ovarian carcinoma is commonly identified in late stages due to comparative lack of early detection and diagnostic techniques in early stages [44]. The delivery and controlled release of therapeutics for site-specific targeted chemotherapy and imaging for early cancer identification are of great pertinence [76,77]. Imaging involves visualization of OC disease development, treatment efficacy and bio-distribution of therapeutics to the tumour, or investigation of molecular biomarkers [78].…”
Section: Diagnosis Of Ovarian Cancer Employing Nanomicellesmentioning
confidence: 99%
“…Polymeric nanomicelle systems, including iodine-containing PLL-PEG nanomicelles, are employed for cancer diagnostic imaging, utilizing conventional sectional tomography (CT) imaging and Single Photon Emission Computed Tomography SPECT using gamma rays. Furthermore, to monitor nanomicelles formulations and exchanges in cancer disease, nanomicelle co-encapsulated with imaging clustered/chelated metallic groups have been employed, for example, in gold compounds, manganese oxide-loaded nanoparticles, as well as being utilized with ultrasound (US) and magnetic resonance imaging (MRI) [76]. Currently, gadolinium (Gd)-contrast medium, including Magnevist ® , are medically employed where visual contrast is increased by limiting the T1 reduction period (period of high longitudinal magnetization with brighter image) of aqueous protons.…”
Section: Diagnosis Of Ovarian Cancer Employing Nanomicellesmentioning
confidence: 99%
“…When nonfunctionalised nanomicelles have significant continual blood circulation period and successfully accumulate in tumour tissue through the passive enhanced permeability effect (EPR), this is indicative of passive targeting [76,108]. The therapeutic payloads are distributed to the tumour extracellular matrix and dispensed into the tumour cells and tissues.…”
Section: Passive Targeting By Enhanced Permeability Effect Of Tumour mentioning
confidence: 99%
“…These properties include the architecture of leaky tumour blood vasculature, impaired lymphatic drainage scheme, and increase in formation of permeability agents [109][110][111][112]. Several passive targeting nanocarrier systems have a PEG coating for stealth and "concealment" properties, including Genexol-PM, SP1049C, NK911, Opaxio™ (formerly Xyotax™), CRLX101, ProLindac™, SPI-77 and CPT-11 [76].…”
Section: Passive Targeting By Enhanced Permeability Effect Of Tumour mentioning
Despite advances achieved in medicine, chemotherapeutics still has detrimental side effects with ovarian cancer (OC), accounting for numerous deaths among females. The provision of safe, early detection and active treatment of OC remains a challenge, in spite of improvements in new antineoplastic discovery. Nanosystems have shown remarkable progress with impact in diagnosis and chemotherapy of various cancers, due to their ideal size; improved drug encapsulation within its interior core; potential to minimize drug degradation; improve in vivo drug release kinetics; and prolong blood circulation times. However, nanodrug delivery systems have few limitations regarding its accuracy of tumour targeting and the ability to provide sustained drug release. Hence, a cogent and strategic approach has focused on nanosystem functionalization with antibody-based ligands to selectively enhance cellular uptake of antineoplastics. Antibody functionalized nanosystems are (advanced) synthetic candidates, with a broad range of efficiency in specific tumour targeting, whilst leaving normal cells unaffected. This article comprehensively reviews the present status of nanosystems, with particular emphasis on nanomicelles for molecular diagnosis and treatment of OC. In addition, biomarkers of nanosystems provide important prospects as chemotherapeutic strategies to upsurge the survival rate of patients with OC.
“…Ovarian carcinoma is commonly identified in late stages due to comparative lack of early detection and diagnostic techniques in early stages [44]. The delivery and controlled release of therapeutics for site-specific targeted chemotherapy and imaging for early cancer identification are of great pertinence [76,77]. Imaging involves visualization of OC disease development, treatment efficacy and bio-distribution of therapeutics to the tumour, or investigation of molecular biomarkers [78].…”
Section: Diagnosis Of Ovarian Cancer Employing Nanomicellesmentioning
confidence: 99%
“…Polymeric nanomicelle systems, including iodine-containing PLL-PEG nanomicelles, are employed for cancer diagnostic imaging, utilizing conventional sectional tomography (CT) imaging and Single Photon Emission Computed Tomography SPECT using gamma rays. Furthermore, to monitor nanomicelles formulations and exchanges in cancer disease, nanomicelle co-encapsulated with imaging clustered/chelated metallic groups have been employed, for example, in gold compounds, manganese oxide-loaded nanoparticles, as well as being utilized with ultrasound (US) and magnetic resonance imaging (MRI) [76]. Currently, gadolinium (Gd)-contrast medium, including Magnevist ® , are medically employed where visual contrast is increased by limiting the T1 reduction period (period of high longitudinal magnetization with brighter image) of aqueous protons.…”
Section: Diagnosis Of Ovarian Cancer Employing Nanomicellesmentioning
confidence: 99%
“…When nonfunctionalised nanomicelles have significant continual blood circulation period and successfully accumulate in tumour tissue through the passive enhanced permeability effect (EPR), this is indicative of passive targeting [76,108]. The therapeutic payloads are distributed to the tumour extracellular matrix and dispensed into the tumour cells and tissues.…”
Section: Passive Targeting By Enhanced Permeability Effect Of Tumour mentioning
confidence: 99%
“…These properties include the architecture of leaky tumour blood vasculature, impaired lymphatic drainage scheme, and increase in formation of permeability agents [109][110][111][112]. Several passive targeting nanocarrier systems have a PEG coating for stealth and "concealment" properties, including Genexol-PM, SP1049C, NK911, Opaxio™ (formerly Xyotax™), CRLX101, ProLindac™, SPI-77 and CPT-11 [76].…”
Section: Passive Targeting By Enhanced Permeability Effect Of Tumour mentioning
Despite advances achieved in medicine, chemotherapeutics still has detrimental side effects with ovarian cancer (OC), accounting for numerous deaths among females. The provision of safe, early detection and active treatment of OC remains a challenge, in spite of improvements in new antineoplastic discovery. Nanosystems have shown remarkable progress with impact in diagnosis and chemotherapy of various cancers, due to their ideal size; improved drug encapsulation within its interior core; potential to minimize drug degradation; improve in vivo drug release kinetics; and prolong blood circulation times. However, nanodrug delivery systems have few limitations regarding its accuracy of tumour targeting and the ability to provide sustained drug release. Hence, a cogent and strategic approach has focused on nanosystem functionalization with antibody-based ligands to selectively enhance cellular uptake of antineoplastics. Antibody functionalized nanosystems are (advanced) synthetic candidates, with a broad range of efficiency in specific tumour targeting, whilst leaving normal cells unaffected. This article comprehensively reviews the present status of nanosystems, with particular emphasis on nanomicelles for molecular diagnosis and treatment of OC. In addition, biomarkers of nanosystems provide important prospects as chemotherapeutic strategies to upsurge the survival rate of patients with OC.
“…and have shown potential in inhibiting of various types of cancers (Wang et al, 2017;Han et al, 2019;Rahbarghazi et al, 2019;Wu et al, 2019) For the site-specific local treatment and chemoprevention of oral squamous cell carcinoma, several polymeric drug delivery systems have been developed using nanotechnology which has shown enhanced activity (Desai, 2018;Ketabat et al, 2019). Some studies include drugs nanoformulations such as naringenin NPs, ellagic acid chitosan NPs, which showed significant enhancement in both bioavailability and efficacy (Arulmozhi et al, 2013;Sulfikkarali et al, 2013;Desai, 2018). In addition, cisplatin when encapsulated in polymeric micelles was reported to eliminate cisplatin induced nephrotoxicity (Endo et al, 2013;Desai, 2018).…”
Cancer research in pursuit of better diagnostic and treatment modalities has seen great advances in recent years. However, the incidence rate of cancer is still very high. Almost 40% of women and men are diagnosed with cancer during their lifetime. Such high incidence has not only resulted in high mortality but also severely compromised patient lifestyles, and added a great socioeconomic burden. In view of this, chemoprevention has gained wide attention as a method to reduce cancer incidence and its relapse after treatment. Among various stems of chemoprevention research, nanotechnology-based chemoprevention approaches have established their potential to offer better efficacy and safety. This review summarizes recent advances in nanotechnology-based chemoprevention strategies for various cancers with emphasis on lung and bronchial cancer, colorectal, pancreatic, and breast cancer and highlights the unmet needs in this developing field towards successful clinical translation.
In recent times mucoadhesive drug delivery systems are gaining popularity in oral cancer. It is a malignancy with high global prevalence. Despite significant advances in cancer therapeutics, improving the prognosis of late‐stage oral cancer remains challenging. Targeted therapy using mucoadhesive polymers can improve oral cancer patients' overall outcome by offering enhanced oral mucosa bioavailability, better drug distribution and tissue targeting, and minimizing systemic side effects. Mucoadhesive polymers can also be delivered via different formulations such as tablets, films, patches, gels, and nanoparticles. These polymers can deliver an array of medicines, making them an adaptable drug delivery approach. Drug delivery techniques based on these mucoadhesive polymers are gaining traction and have immense potential as a prospective treatment for late‐stage oral cancer. This review examines leading research in mucoadhesive polymers and discusses their potential applications in treating oral cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.